Description |
S-3304 is a novel matrix metalloproteinases (MMP) inhibitor specific for MMP-2 and MMP-9.
|
Related Catalog |
|
Target |
MMP-9
|
In Vitro |
S 3304 is a novel D-tryptophan derivative and a potent, orally active, noncytotoxic Matrix metalloproteinases inhibitor (MMPI). Biochemical studies show that S 3304 most potently inhibits the activities of MMP-2 and MMP-9 but does not inhibit MMP-1, MMP-3, or MMP-7 and may, therefore, lack the musculoskeletal side effects seen with nonspecific inhibitors[1].
|
In Vivo |
In vivo pharmacologic studies have shown that the oral administration of S 3304, at a dose range of 20 to 200 mg/kg, inhibits angiogenesis, artificially induced in mice by the dorsal air-sac method. Similar oral doses of S 3304 result in potent inhibition of metastatic lung colonization of Lewis murine lung carcinoma injected via tail vein and liver metastasis of C-1H human colon cancer implanted into the spleen[1].
|
References |
[1]. Chiappori AA, et al. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res. 2007 Apr 1;13(7):2091-9.
|